<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04553523</url>
  </required_header>
  <id_info>
    <org_study_id>CP 18-001</org_study_id>
    <nct_id>NCT04553523</nct_id>
  </id_info>
  <brief_title>Hydrus(R) Microstent New Enrollment Post-Approval Study</brief_title>
  <official_title>The Hydrus(R) Microstent New Enrollment Post-Approval Study: A Prospective, Non-Randomized, Multicenter, Single Arm, Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ivantis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ivantis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the rate of Hydrus Microstent malposition and associated clinical sequelae&#xD;
      occurring within 24 months post-operation. This trial is a prospective, non-randomized,&#xD;
      multicenter, single arm, post approval study. Qualified subjects will undergo uncomplicated&#xD;
      cataract surgery with placement of a monofocal intraocular lens (IOL), followed by&#xD;
      implantation of the Hydrus Microstent.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2020</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of clinically significant device malposition</measure>
    <time_frame>24 Months</time_frame>
    <description>Rate of occurrence of clinically significant device malposition associated with clinical sequelae</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of intraoperative ocular adverse events</measure>
    <time_frame>24 Months</time_frame>
    <description>Rate of occurrence of intraoperative ocular adverse events including: hyphema obscuring the surgeon's view, choroidal hemorrhage or effusion, choroidal detachment, significant iris injury or trauma, corneal abrasion, corneal edema, zonular dialysis, cyclodialysis, cyclodialysis cleft, iridodialysis, vitreous loss not associated with the cataract procedure, inadvertent perforation of the sclera, Descemet's membrane detachment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of sight threatening post-operative adverse events</measure>
    <time_frame>24 Months</time_frame>
    <description>Rate of occurrence of sight threatening, post-operative adverse events including: endophthalmitis, corneal decompensation, severe retinal detachment, severe choroidal hemorrhage, severe choroidal detachment, aqueous misdirection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of other postoperative ocular adverse events</measure>
    <time_frame>24 Months</time_frame>
    <description>Rate of occurrence of other postop ocular adverse events including: anterior uveitis/iritis, non-persistent &amp; persistent, BCVA loss of 2 lines or more, chronic pain, device migration, device obstruction, PAS, ocular secondary surgical interventions for IOP or glaucoma management, hypotony at or after 1 month postop, hyphema, corneal opacification, corneal edema persisting or severe corneal edema, other retinal complications, elevated mean IOP &gt;/=10mmHg vs screening, iris prolapse/wound incarceration, significant foreign body sensation at or after 3 months postop, surgical re-intervention, worsening of visual field.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Occurrence of non-clinically significant device malposition</measure>
    <time_frame>24 Months</time_frame>
    <description>Rate of occurrence of device malposition that is not clinically significant (ie, does not result in clinical sequelae)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects with mild to moderate POAG undergoing cataract surgery &amp; implantation of the Hydrus Microstent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hydrus Microstent</intervention_name>
    <description>The Hydrus Microstent is a crescent-shaped nitinol device intended to be a permanent implant placed through the trabecular meshwork into Schlemm's canal, immediately following placement of a monofocal IOL</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  An operable age-related cataract with BCVA of 20/40 or worse&#xD;
&#xD;
          -  Diagnosis of POAG treated with no more than 4 topical hypotensive medications&#xD;
&#xD;
          -  Optic nerve appearance characteristic of glaucoma&#xD;
&#xD;
          -  Medicated IOP &lt;/= 31mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Closed angle forms of glaucoma&#xD;
&#xD;
          -  Congenital or developmental glaucoma&#xD;
&#xD;
          -  Secondary glaucoma&#xD;
&#xD;
          -  Use of more than 4 ocular hypotensive medications&#xD;
&#xD;
          -  Previous argon laser trabeculoplasty, trabeculectomy, tube shunts, or any other prior&#xD;
             filtration or cilioablative surgery&#xD;
&#xD;
          -  Prior surgery with implanted device or other surgery involving the trabecular meshwork&#xD;
             or Schlemm's canal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Richard Hope, MD</last_name>
    <phone>949-333-1310</phone>
    <email>rhope@ivantisinc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sacramento Eye Consultants, A Medical Corporation</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Brubaker, MD</last_name>
      <email>jbrubaker@saceye.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eye Center of Northern Colorado</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kent Bashford, MD</last_name>
      <email>K.Bashford@eyecenternoco.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fraser Eye Care Center</name>
      <address>
        <city>Fraser</city>
        <state>Michigan</state>
        <zip>48026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahdi Basha, MD</last_name>
      <email>mahdib@frasereye.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Suburban Eye Specialists</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Wandling, MD</last_name>
      <email>gwandling@nseyespecialists.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Sight</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Liang, MD</last_name>
      <email>evaliang11@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolina Eye Associates</name>
      <address>
        <city>Southern Pines</city>
        <state>North Carolina</state>
        <zip>28387</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Winston Garris, MD</last_name>
      <email>winston.garris@carolinaeye.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anup Khatana, MD</last_name>
      <email>akhatana@cvphealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>El Paso Eye Surgeons, PA</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Gallardo, MD</last_name>
      <email>gallardomark@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Eye &amp; Laser Center</name>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <zip>76054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Hu, MD</last_name>
      <email>jerryganghu@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Eye Centers of Racine and Kenosha LTD</name>
      <address>
        <city>Kenosha</city>
        <state>Wisconsin</state>
        <zip>53142</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Inder Paul Singh, MD</last_name>
      <email>ipsingh@amazingeye.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 11, 2020</study_first_submitted>
  <study_first_submitted_qc>September 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

